Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Ipragliflozin
45
CHF
CHF 45.00
In stock
AG-CR1-3546-M01010 mgCHF 45.00
AG-CR1-3546-M05050 mgCHF 160.00
| Product Details | |
|---|---|
| Synonyms | ASP1941 |
| Product Type | Chemical |
| Properties | |
| Formula |
C21H21FO5S |
| MW | 404.5 |
| CAS | 761423-87-4 |
| Purity Chemicals | ≥98% |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO, DMF or ethanol (all 20mg/ml). |
| InChi Key | AHFWIQIYAXSLBA-RQXATKFSSA-N |
| Smiles | FC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)=C2)=C2CC3=CC4=CC=CC=C4S3 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Ipragliflozin is an orally active, highly potent sodium glucose co-transporter 2 (SGLT-2) inhibitor (IC50 = 7.4nM), selective over SGLT-1, 3, 4, 5 and 6. SGLT-2 is one subtype of SGLTs found almost exclusively in the proximal tubules of nephronic components in kidneys, playing a key role in the re-uptake of glucose in the proximal tubule of the kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE).
- Anti-diabetic and anti-obesity agent. Shown to improve glycemic control and reduce body weight, furthermore, lowering hypoglycemic risk and abdominal symptoms. SGLT-2 inhibitors are likely to improve β-cell function and insulin sensitivity and restore glucose homeostasis.
- Attenuates non-alcoholic steatohepatitis (NASH) development.
Product References
- Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo: A. Tahara, et al.; Naunyn Schmiedebergs Arch. Pharmacol. 385, 423 (2012)
- Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus: M. Imamura, et al.; Bioorg. Med. Chem. 20, 3263 (2012)
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice: A. Tahara, et al.; Eur. J. Pharmacol. 715, 246 (2013)
- Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin: M. Takahara, et al.; Endocr. J. 62, 77 (2015)
- Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus: T. Kawata, et al.; J. Clin. Med. Res. 9, 586 (2017)
- In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor: T. Takasu, et al.; Biol. Pharm. Bull. 42, 507 (2019)
- Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules: K. Hosokawa, et al.; Int. J. Mol. Sci. 26, 190 (2019)
- SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation: S. Komatsu, et al.; Endocr. J. 67, 99 (2020)
- Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model: A. Morishita, et al.; PLoS One 17, e0261310 (2022)
Related Products
